{
  "docId": "019de075-8e2a-754a-82c8-fcf95d1468e0",
  "docSlug": "7b6af1cd1f41a47a828e775322659278",
  "documentTitle": "Exscientia | Results Presentation Deck | 19 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 19,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide outlines a standard oncology clinical trial design (Phase 1/2) with a transition point at RP2D (Recommended Phase 2 Dose).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8e2a-754a-82c8-fcf95d1468e0/12",
  "deckHref": "/decks/019de075-8e2a-754a-82c8-fcf95d1468e0",
  "deckJsonHref": "/decks/019de075-8e2a-754a-82c8-fcf95d1468e0.json",
  "deckAnchorHref": "/decks/019de075-8e2a-754a-82c8-fcf95d1468e0#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.67,
        "x": 0.24,
        "y": 0.33
      },
      "kind": "diagram",
      "text": "Two-part trial design showing Part 1 (Dose Escalation) leading to Part 2 (Dose Expansion) via RP2D",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f0feb64-8143-470c-9f0c-b95363b707aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.86,
        "x": 0.07,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "ELUCIDATE (protocol number GTAEXS617-001) is a Phase 1/2 open-label multi-centre study to assess the safety, pharmacokinetics and anti-tumour activity of GTAEXS617 in patients with advanced solid tumours (who have failed on, refused or are ineligible for the standard of care (SoC))",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04991aa6-cb1d-46d6-9326-a8477062bfec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "Additional data generation, including clinical endpoints, peripheral and tumour multi-omics, and correlation of data and response to previously collected ex vivo results planned",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf3f06ae-5cd4-447f-bdeb-dd2d13fbfb77",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Preclinically identified PD biomarkers to be further assessed in the trial",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e16fcdb1-da0f-44b7-9409-86c70e0843a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "ELUCIDATE: '617 Phase 1/2 ongoing in advanced solid tumours",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "93e75667-ca5f-4b43-a339-e69728d3840b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "c17bb5f0-4b1c-462c-8c61-49ba80425461",
      "evidence": "Standard oncology trial structure (Part 1/Part 2)",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "2dc81f1e-81e1-42a7-9d14-d7b851539fd2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Slides 9-14 provide updates on clinical programmes and CDK7",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 10,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "e0ea903c-a616-4ffc-ade5-b44992f180ef",
      "evidence": "The slides provide data and insights on clinical programmes and CDK7",
      "position": 0,
      "objective": "To identify patterns in clinical programmes and CDK7 update",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}